147 related articles for article (PubMed ID: 20535964)
1. [Clinical development of biomarkers for personalized medicine].
Saito M; Yoshino T
Nihon Rinsho; 2010 Jun; 68(6):1111-6. PubMed ID: 20535964
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer.
Lieberman R
Am J Ther; 2009; 16(6):477-9. PubMed ID: 19829092
[No Abstract] [Full Text] [Related]
4. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
5. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
6. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
7. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
Bertagnolli MM
J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
[No Abstract] [Full Text] [Related]
8. Innovative personalized medicine in gastric cancer: time to move forward.
Lee J; Kim KM; Kang WK; Ou SH
Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
[TBL] [Abstract][Full Text] [Related]
9. Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer.
Al-Hajeili M; Shields AF; Hwang JJ; Wadlow RC; Marshall JL
Oncology (Williston Park); 2017 Apr; 31(4):301-12. PubMed ID: 28412781
[TBL] [Abstract][Full Text] [Related]
10. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
Chua W; Moore MM; Charles KA; Clarke SJ
Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.
Erstad DJ; Tumusiime G; Cusack JC
Ann Surg Oncol; 2015 Oct; 22(11):3433-50. PubMed ID: 26215192
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
Wang HL; Lopategui J; Amin MB; Patterson SD
Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
15. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
Wong R; Cunningham D
J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
[No Abstract] [Full Text] [Related]
16. [Predictive biomarkers in colorectal cancer].
Bosman FT
Rev Med Suisse; 2009 Jul; 5(211):1513-8. PubMed ID: 19694362
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
Cancer J; 2009; 15(2):110-3. PubMed ID: 19390304
[TBL] [Abstract][Full Text] [Related]
18. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
19. Impact of molecular markers on treatment selection in advanced colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Eur J Cancer; 2009 Sep; 45 Suppl 1():70-8. PubMed ID: 19775606
[No Abstract] [Full Text] [Related]
20. KRAS mutation screening in colorectal cancer: From paper to practice.
Fakih MM
Clin Colorectal Cancer; 2010 Jan; 9(1):22-30. PubMed ID: 20100685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]